Authors
Wanqiu Peng, Tingting Xu, Zhenhai Zhang, Li Cui, Chao Gu, Xiaomeng Sun, Hui Li
Published in
Naunyn-Schmiedeberg's archives of pharmacology. Jun 25, 2026. Epub Jun 25, 2026.
Abstract
Cinnamon oil exhibits therapeutic potential against constipation-predominant irritable bowel syndrome (IBS-C). This study aimed to evaluate the efficacy and mechanisms of its main components-cinnamaldehyde (CAL), cinnamyl alcohol (COL), and trans-cinnamic acid (TCA)-in IBS-C. This study established an IBS-C mouse model using loperamide hydrochloride and restraint stress, and evaluated indicators such as body weight, the number of fecal pellets, fecal water content, visceral hypersensitivity, and small intestinal propulsion rate. The analysis was performed via HE staining, ELISA, Western blot, qRT-PCR, and 16S rRNA sequencing. All three components ameliorated low-grade immune cell infiltration in colonic tissue and reduced serum levels of IL-6, IL-8, and TNF-α. They also increased motilin (MTL) and acetylcholine (Ach) levels; all except trans-cinnamic acid low-dose (TCA-L) increased gastrin (Gas) levels, and all except TCA-L and trans-cinnamic acid high-dose (TCA-H) increased 5-HT levels. Cinnamaldehyde high-dose (CAL-H), cinnamyl alcohol high-dose (COL-H), and TCA-H upregulated the expression of tryptophan hydroxylase 1 (TPH1), serotonin transporter (SERT), and 5-hydroxytryptamine receptor 4 (5-HT4R) and partially modulated gut microbiota composition. CAL showed favorable effects under the present experimental conditions. The three components alleviated IBS-C symptoms partially through modulating the 5-HT signaling pathway and gut microbiota, with CAL showing the most pronounced effects under the present experimental conditions.
PMID:
42347879
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0